EANS-Adhoc: Sartorius AG
Order intake and sales revenue substantially
increased for both divisions | Positive earnings contributed by the Mechatronics
Division | Group operating earnings jumped nearly 50% | Expectations for 2010
confirmed
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement.
Figures for the First Half of 2010
23.07.2010
In the first half of 2010, order intake for the Sartorius Group climbed 9.8% (currency-adjusted: +8.4%) from EUR306.4 million to EUR336.4 million. Sales revenue rose 6.3% (currency-adj.: +5.1%) to EUR315.2 million from EUR296.5 million a year ago. The Biotechnology Division received orders valued at EUR221.4 million, up from EUR203.5 million in the previous year, a plus of 8.8% (currency-adj.: +7.4%), and increased its sales revenue 5.7% (currency-adj.: +4.6%) to EUR209.1 from EUR197.8 million a year earlier. The Mechatronics Division posted a significant gain in order intake of 11.8% (currency-adj.: +10.4%) to EUR115.1 million from EUR102.9 million in the previous year; its sales revenue grew 7.5% (currency-adj.: +6.1%) to EUR106.1 million, up from EUR98.7 million a year ago.
Consolidated earnings before interest, taxes and amortization and adjusted for extraordinary expenses of EUR1.9 million (prev. year: EUR16.3 mn) underlying EBITA surged 47.0% to EUR36.3 million, up from EUR24.7 million a year earlier; the respective margin rose from 8.3% to 11.5%. The Biotechnology Division contributed an underlying EBITA of EUR31.5 million, up from EUR28.0 million a year ago, which means its margin increased from 14.2% to 15.0%. After posting a loss of EUR3.4 million in the year-earlier period, the Mechatronics Division contributed a positive result to Group earnings, reporting an underlying EBITA of EUR4.8 million and improving its profit margin from -3.4% to 4.5%.
Excluding non-cash amortization, underlying net profit after minority interest for the first half totals EUR15.9 million (prev. year: EUR6.4 mn); the respective earnings per share are at EUR0.93, up from EUR0.37 a year ago.
The results achieved meet our expectations for both divisions and confirm our outlook for the current fiscal year. This outlook forecasts sales growth of slightly above 5% in constant currencies and further improvement of the operating EBITA margin by one to two percentage points as well as a significantly positive operating cash flow.
Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will discuss the results with analysts and investors on Monday, July 26, at 4:00 p.m. Central European Time in a webcast teleconference. You may dial into the teleconference starting at 3:45 p.m. CET at the following numbers: Germany +49 (0)69 2222 2245; France +33 (0)1 70 99 42 73; UK +44 (0)20 7138 0824; USA +1 212 444 0481 The dial-in code is as follows: 4383672 The webcast and presentation can be viewed at www.sartorius.com.
end of announcement euro adhoc
Further inquiry note:
Andreas Wiederhold
Team Leader Treasury & Investor Relations
Telefon: +49 (0)551 308-1668
E-Mail: andreas.wiederhold@sartorius.com
Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade